Context Therapeutics Inc. announced on October 16, 2024, that a poster regarding its clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody, will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The meeting is scheduled for November 8–10, 2024, in Houston, TX.
The presentation will focus on CTIM-76, which targets Claudin 6 (CLDN6), a protein highly expressed in various solid tumors including ovarian, endometrial, lung, gastric, and testicular cancers. Preclinical research suggests that CTIM-76 has the potential for convenient dosing and low immunogenicity risk.
This presentation highlights the ongoing preclinical development and characterization of CTIM-76, supporting its advancement as a T cell engager. The data aims to address the significant number of patients potentially eligible for CTIM-76 therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.